Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

T2 Biosystems Announces Presentations at IDWeek 2017


Posted on: 21 Sep 17

LEXINGTON, Mass., Sept. 21, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced a panel presentation and six poster presentations during the IDWeek 2017 Conference in San Diego, CA, held October 4-8. The panel presentation will be focused on the positive impact of the T2Candida Panel, early experiences with the T2Bacteria Research Use Only (RUO) Panel and how the development of a diagnostic panel to detect Gram-negative bacterial species and antibiotic resistance should impact antimicrobial stewardship. Attendees are invited to visit T2 Biosystems at Booth #311 throughout the IDWeek Conference, where the Company will offer live demonstrations of their diagnostic capabilities at the booth.

“We are excited for IDWeek attendees to learn more about T2 Biosystems’ full line of diagnostic products and capabilities,” said John McDonough, president and chief executive officer. “Through a range of abstracts and presentations during the show, we will be sharing customer experiences with the T2Sepsis Solution, including the T2Bacteria RUO Panel.”

A schedule of relevant presentations is as follows: 

PANEL PRESENTATION:  
TITLE: T2Sepsis Solution: The Impact of Direct from Whole Blood Diagnostics on the Management of Bloodstream Infections (T2Candida and the T2Bacteria RUO Panel)
Presenters:

  • Cornelius J. Clancy, M.D., Associate Professor of Medicine, Director, Mycology Program - University of Pittsburgh, Chief, Infectious Diseases Section - VA Pittsburgh Healthcare System
  • Glen T. Hansen, Ph.D., Director of Clinical Microbiology and Molecular Diagnostics - Hennepin County Medical Center, Minneapolis, MN
  • Urania Rappo, M.D., Ph.D., Director, Medical and Clinical Affairs, Allergan;
  • Rahul Dhanda, Senior Vice President, Marketing & Business Development, T2 Biosystems

Overview: The panel will share their experiences using the T2Sepsis Solution, a unique approach that combines the standard of care in the management of sepsis patients with T2 Biosystems' tests that identify sepsis-causing pathogens without blood culture in 3 to 5 hours with a sensitivity and specificity of over 90%.  Speakers will highlight how the FDA-cleared T2Candida Panel is delivering significant improvements in patient care, share early experiences with the T2Bacteria RUO Panel, and discuss how the development of a diagnostic panel to detect Gram-negative bacterial species and antibiotic resistance will likely impact antimicrobial stewardship. 
Time: October 4th, 7:00-8:00 a.m. PDT
Location: San Diego Convention Center, Room 9

POSTER PRESENTATIONS:
TITLE:  Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel
Session Title:  Oral Abstract Session: The Fungus Among-us – Clinical Advances
Poster Number: #1774
Presenter: Cornelius J. Clancy, M.D., Associate Professor of Medicine, Director, Mycology Program - University of Pittsburgh, Chief, Infectious Diseases Section - VA Pittsburgh Healthcare System
Time: October 7th, 8:30 a.m. PDT
Location: Room 01AB 

TITLE:  Utilization of the T2Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
Session Title:  Poster Abstract Session: Diagnostics - Mycology
Poster Number: #2066
Presenter:  Mohammed Abdulhaleem, M.D., Internal Medicine, UAB-Huntsville campus
Time: October 7th, 12:30-2:00 p.m. PDT
Location: Poster Hall CD 

TITLE:  Relationship of T2Candida Panel to Disease Severity, Mortality and Time to Therapy in Patients with Candidemia
Session Title:  Poster Abstract Session: Diagnostic - Mycology
Poster Number: #2067
Presenter: Orlando D. Turner, M.D., Division of Infectious Diseases, University of Alabama at Birmingham
Time: October 7th, 12:30 PM-2:00 p.m. PDT
Location: Poster Hall CD

TITLE:  Automated Detection of Candida auris Direct from Whole Blood by T2MR
Session Title:  Poster Abstract Session: Diagnostics - Mycology
Poster Number: #2069
Presenter: T2 Biosystems
Time: October 7th, 12:30-2:00 p.m. PDT
Location: Poster Hall CD 

TITLE:  Does a Negative Rapid Diagnostic Test for Detection of Candida Bloodstream Infection Lead to Less Antifungal Use?
Session Title:  Poster Abstract Session: Diagnostics - Mycology
Poster Number: #2081
Presenter: Tanya Bhowmick, M.D., Rutgers Robert Wood Johnson Medical School
Time: October 7th, 12:30-2:00 p.m. PDT
Location: Poster Hall CD 

TITLE:  Influence of T2Candida Testing for Rapid Diagnosis of Candida Infections on Antifungal Stewardship Efforts at a Large Academic Medical Center: A Retrospective, Single-Center Study
Session Title:  Poster Abstract Session: Stewardship: Impact of Diagnostics
Poster Number: #2137
Presenter: Justin F. Hayes, M.D., Division of Infectious Diseases, University of Alabama at Birmingham
Time: October 7th, 12:30-2:00 p.m. PDT
Location: Poster Hall CD 

About T2 Biosystems
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis SolutionTM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding , product pipeline, anticipated product benefits, goals and strategic priorities, product expansion or opportunities, growth expectations or targets and FDA  clearance, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials;  (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes;  (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission, or SEC, on March 15, 2017, and other filings the company makes with the SEC from time to time.  These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, one should not assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803

Media Contact:
Amy Phillips, Feinstein Kean Healthcare
amy.phillips@fkhealth.com
412-327-9499

Investor Contact:
Chris Brinzey, Westwicke Partners
chris.brinzey@westwicke.com
339-970-2843

 

GlobeNewswire
globenewswire.com

Last updated on: 22/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.